| Document |
Document Title |
|
JP2021059539A |
To provide a dysuria-alleviating agent useful for treating or alleviating (or mitigating) dysuria regardless of the presence or degree of prostatomegaly.A dysuria-alleviating agent includes, as an active ingredient, a 2-oxapregnane compo...
|
|
JP6835867B2 |
The present invention relates to a composition for preventing hair loss and, more specifically, to a compound having a structure in which finasteride and a peptide are linked through a covalent bond and a pharmaceutical composition or a ...
|
|
JP6827942B2 |
The present invention belongs to the field of natural medicines and medicinal chemistry, and relates to novel esterified amino acid derivatives of triptolide of general formula I and general formula II or pharmaceutically acceptable addu...
|
|
JP6781148B2 |
The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.
|
|
JP6708670B2 |
Novel homo-aza-steroidal esters with alkylating bis(2-chloroethyl)aminophenoxy propanoic acid and substituted derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the treatment of c...
|
|
JP2019519571A |
Compounds with drug and bio-affecting properties, their pharmaceutical compositions and methods of use are described. Specifically, a aza-substituted triterpenoid compound having a unique antiviral activity represented by the compound of...
|
|
JP2017105827A |
To provide methods of halogenating a carbon-containing compound having an sp3 C-H bond.Methods of halogenating a carbon-containing compound having an sp3 C-H bond are provided. Methods of fluorinating a carbon-containing compound compris...
|
|
JP5769726B2 |
Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to ...
|
|
JP5640009B2 |
The present invention provides a sterol derivative or a pharmaceutically acceptable salt thereof having an activity to promote proliferation of neural stem cells. Namely, the present invention provides a sterol derivative represented by ...
|
|
JP5637426B2 |
To provide a new kinesin inhibitor and a candidate compound of an anticancer agent.This new compound is expressed by formula (I) or its pharmaceutically acceptable salt, and the kinesin inhibitor comprising the compound, a pharmaceutical...
|
|
JP5583976B2 |
The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
|
|
JP5506403B2 |
A proliferation promoting agent for neural stem cells, which comprises a compound produced by Penicillium sp. CND1007 (FERM BP-10917) or a pharmaceutically acceptable salt thereof, as an active ingredient; a novel compound produced by Pe...
|
|
JP2014501280A |
Provided herein are novel crystalline forms of Compound 1. Also provided herein are compositions and methods of uses for the crystalline forms of Compound 1.
|
|
JP2013545815A |
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula Z, IX, X, XI, XII, XIII, XIV, XV, XVI, or XVII. Also described herein are pharmaceutical compositions that include at least one compound described herein an...
|
|
JP5339637B2 |
The invention is related to the area of new 6-Oxa-8α-steroid estrogen analogues and the synthesis of these new biological active steroid estrogen analogues, namely, to the preparation of 6-oxa-8α-steroid estrogens and their use as estr...
|
|
JP5268975B2 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP5252765B2 |
|
|
JP5230451B2 |
The present invention is directed to tetracyclic steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.
|
|
JP2013506686A |
The present disclosure relates to methods for the modulation of autophagy and the treatment of autophgy-related diseases, including cancer, neurodegenerative diseases and pancreatitis.
|
|
JP5144543B2 |
There is provided a compound having Formula I wherein G is a fluorocarbyl group, and wherein R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.
|
|
JP5043250B2 |
This invention relates to novel inhibitors of androgen synthesis that are useful in the treatment of prostate cancer and benign prostatic hypertrophy. The present invention also provides methods of synthesizing these novel compounds, pha...
|
|
JP4981668B2 |
The invention relates to a process for the preparation of 4-steroids of the formula R 1 and R 2 are independently selected from the group consisting of hydrogen, F, Cl, Br, I, C 1-6 -alkyl and C 1-6 -alkoxy, and R 4 is selected from the ...
|
|
JP4866740B2 |
Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, sebor...
|
|
JP2011529485A |
The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatas...
|
|
JP4832303B2 |
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the ...
|
|
JP4827189B2 |
Process of oxidizing an alcohol in an amide solvent with use of a mixed reagent containing hydrogen peroxide and a tungsten catalyst.
|
|
JPWO2009136629A1 |
A step of contacting a prostate cancer cell with a test substance to measure the mRNA expression level or a prostate-specific antigen production level of the prostate-specific antigen in the prostate cancer cell, and contacting the adipo...
|
|
JP2011162532A |
To provide a production method of brassinosteroid-like substances excellent in functions and effects improving with microdose, various vegetable physiological activity such as plant growth promotion, vessel bundle differentiation promoti...
|
|
JP4664433B2 |
New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, s...
|
|
JP4608674B2 |
|
|
JP4563032B2 |
Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the f...
|
|
JP4553586B2 |
There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R<1> is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhi...
|
|
JP4516839B2 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP4516316B2 |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP4474921B2 |
A process to produce 2,5-bis(trifluoromethyl)nitrobenzene in a high yield from an industrially easily available material by using a substance with which the reaction operation is simple and handling is easy, with a small number of steps ...
|
|
JP2010511648A |
The present invention relates to the use of cholesterylamines in the preparation of pharmaceutical compositions. These pharmaceutical compositions are to be used in the medical intervention of infectious diseases, in particular diseases ...
|
|
JP2010024238A |
To provide an enzyme inhibitor strongly inhibiting 17-hydroxylase/C17,20-lyase and 5-reductase, blocking all androgen synthesis, and useful in treatment of prostatic cancer and benign prostatic hypertrophy, based on defects associated wi...
|
|
JP2009215317A |
To provide a sulfatase inhibitor which needs a compound limiting or preventing the usage of estrogen in hormone-dependent tumor, and does not have an estrogenic active component.The invention relates to a new estratriene expressed by gen...
|
|
JP4308824B2 |
A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with ...
|
|
JP2009527494A |
The present invention is directed to 7 oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocort...
|
|
JP2009518404A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
JP4257117B2 |
An improved process for preparing steriods, such as 3-oxo-4-azasteroids, is described. Compounds of this type are known to be useful in the preparation of compounds having 5a-reductase inhibitor activity. The process comprises the hydrog...
|
|
JP4226552B2 |
This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in t...
|
|
JP2008540416A |
The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or ...
|
|
JP2008273866A |
To provide a new anticancer agent containing a brassinosteroid derivative.This anticancer agent contains the brassinosteroid derivative which is a plant physiologically active material, as an active ingredient. The brassinosteroid does n...
|
|
JP2008535850A |
The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, method...
|
|
JP2008515984A |
The present invention relates to compounds of formula I: wherein R1, R2, R3, and R8 are defined herein.
|
|
JP2008510811A |
Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen defici...
|
|
JP2008507542A |
This invention provides for combinations of 5 alpha reductase inhibitors and SERMs. These combinations are useful in: 1) preventing prostate carcinogenesis in a subject; 2) preventing the recurrence of, suppressing, inhibiting or reducin...
|
|
JP2007534757A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
